Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized,Single-Blind, Placebo-controlled, Self-matched Pairing, Independent Evaluated Study to Evaluate the Efficacy and Safety of RGN-137 Topical Gel in Subjects With Junctional and Dystrophic Epidermolysis Bullosa (CELEB)

Next Previous
Trial Profile

A Randomized,Single-Blind, Placebo-controlled, Self-matched Pairing, Independent Evaluated Study to Evaluate the Efficacy and Safety of RGN-137 Topical Gel in Subjects With Junctional and Dystrophic Epidermolysis Bullosa (CELEB)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 03 Sep 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Timbetasin (Primary)
  • Indications Epidermolysis bullosa
  • Focus Therapeutic Use
  • Acronyms CELEB
  • Sponsors G-treeBNT; Lenus Therapeutics

    • Most Recent Events

    • 05 Aug 2019 According to a RegeneRx media release, the trial is proceeding well at five hospitals specializing in EB.
    • 05 Aug 2019 According to a RegeneRx media release, the company confirmed that the first patient was enrolled, treated, and complete wound healing was achieved in single-blinded phase 2 study.
    • 05 Aug 2019 Results of complete wound healing on the index lesion of the first subject presented in the Lenus Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top